Bailard’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.03M | Sell |
6,041
-610
| -9% | -$293K | 0.06% | 202 |
|
|
2026
Q1 | $3.27M | Sell |
6,651
-220
| -3% | -$119K | 0.08% | 188 |
|
|
2025
Q4 | $3.98M | Buy |
6,871
+36
| +0.5% | +$20.4K | 0.09% | 161 |
|
|
2025
Q3 | $3.32M | Sell |
6,835
-14
| -0.2% | -$6.52K | 0.07% | 188 |
|
|
2025
Q2 | $2.78M | Buy |
6,849
+4,024
| +142% | +$1.68M | 0.06% | 202 |
|
|
2025
Q1 | $1.41M | Buy |
2,825
+1,153
| +69% | +$624K | 0.04% | 261 |
|
|
2024
Q4 | $870K | Buy |
1,672
+48
| +3% | +$26.4K | 0.02% | 318 |
|
|
2024
Q3 | $1M | Sell |
1,624
-4,449
| -73% | -$2.63M | 0.03% | 304 |
|
|
2024
Q2 | $3.36M | Sell |
6,073
-236
| -4% | -$135K | 0.09% | 171 |
|
|
2024
Q1 | $3.67M | Sell |
6,309
-108
| -2% | -$60.6K | 0.1% | 171 |
|
|
2023
Q4 | $3.41M | Sell |
6,417
-23
| -0.4% | -$11.1K | 0.1% | 171 |
|
|
2023
Q3 | $3.26M | Sell |
6,440
-38
| -0.6% | -$20.2K | 0.11% | 157 |
|
|
2023
Q2 | $3.38M | Sell |
6,478
-35
| -0.5% | -$18.9K | 0.12% | 149 |
|
|
2023
Q1 | $3.75M | Sell |
6,513
-136
| -2% | -$76.7K | 0.13% | 131 |
|
|
2022
Q4 | $3.66M | Sell |
6,649
-55
| -0.8% | -$29.1K | 0.14% | 132 |
|
|
2022
Q3 | $3.4M | Buy |
6,704
+6
| +0.1% | +$3.36K | 0.14% | 135 |
|
|
2022
Q2 | $3.64M | Buy |
6,698
+5
| +0.1% | +$2.75K | 0.14% | 135 |
|
|
2022
Q1 | $3.95M | Sell |
6,693
-27
| -0.4% | -$15.5K | 0.13% | 142 |
|
|
2021
Q4 | $4.48M | Buy |
6,720
+260
| +4% | +$162K | 0.14% | 138 |
|
|
2021
Q3 | $3.69M | Hold |
6,460
| – | – | 0.13% | 147 |
|
|
2021
Q2 | $3.26M | Sell |
6,460
-39
| -0.6% | -$18.4K | 0.11% | 156 |
|
|
2021
Q1 | $2.97M | Buy |
6,499
+5,552
| +586% | +$2.65M | 0.11% | 155 |
|
|
2020
Q4 | $441K | Buy |
947
+204
| +27% | +$95.7K | 0.02% | 355 |
|
|
2020
Q3 | $328K | Sell |
743
-331
| -31% | -$137K | 0.02% | 371 |
|
|
2020
Q2 | $389K | Buy |
1,074
+222
| +26% | +$74.4K | 0.02% | 301 |
|
|
2020
Q1 | $242K | Sell |
852
-627
| -42% | -$198K | 0.02% | 370 |
|
|
2019
Q4 | $480K | Buy |
1,479
+397
| +37% | +$120K | 0.03% | 296 |
|
|
2019
Q3 | $315K | Sell |
1,082
-89
| -8% | -$25.5K | 0.02% | 391 |
|
|
2019
Q2 | $344K | Sell |
1,171
-44
| -4% | -$12.1K | 0.02% | 380 |
|
|
2019
Q1 | $333K | Sell |
1,215
-26
| -2% | -$6.47K | 0.02% | 396 |
|
|
2018
Q4 | $278K | Sell |
1,241
-358
| -22% | -$84K | 0.02% | 435 |
|
|
2018
Q3 | $390K | Buy |
1,599
+300
| +23% | +$69K | 0.02% | 427 |
|
|
2018
Q2 | $269K | Buy |
1,299
+141
| +12% | +$29.9K | 0.02% | 459 |
|
|
2018
Q1 | $239K | Sell |
1,158
-12,857
| -92% | -$2.7M | 0.02% | 440 |
|
|
2017
Q4 | $2.66M | Sell |
14,015
-17,968
| -56% | -$3.44M | 0.17% | 145 |
|
|
2017
Q3 | $6.05M | Buy |
31,983
+1,118
| +4% | +$202K | 0.47% | 49 |
|
|
2017
Q2 | $5.38M | Buy |
30,865
+777
| +3% | +$131K | 0.44% | 54 |
|
|
2017
Q1 | $4.62M | Buy |
30,088
+61
| +0.2% | +$9.32K | 0.38% | 69 |
|
|
2016
Q4 | $4.24M | Buy |
30,027
+954
| +3% | +$141K | 0.39% | 66 |
|
|
2016
Q3 | $4.62M | Buy |
29,073
+13,219
| +83% | +$2.04M | 0.43% | 58 |
|
|
2016
Q2 | $2.34M | Buy |
+15,854
| New | +$2.34M | 0.28% | 87 |
|
Other funds holding TMO
Bailard's TMO Position: Q2 2026 in Review
Bailard reduced its Thermo Fisher Scientific (TMO) stake by 9.2% in Q2 2026, selling an estimated $293K and leaving 6,041 shares worth $3.03M. The position accounts for 0.06% of the portfolio, ranked #202.
Bailard first reported a position in TMO in Q2 2016 and has held it in 41 quarters since. The position peaked at $6.05M in Q3 2017. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Bailard held 6,041 shares of Thermo Fisher Scientific worth $3.03M as of Q2 2026.
- Bailard sold 610 Thermo Fisher Scientific shares in Q2 2026, an estimated $293K.
- Thermo Fisher Scientific made up 0.06% of Bailard's portfolio in Q2 2026, its #202 holding.
- Bailard first reported a position in Thermo Fisher Scientific in Q2 2016 and has held it in 41 quarters since.
- Bailard's Thermo Fisher Scientific position peaked at $6.05M in Q3 2017.
- 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.